Podcasts about Ganti

Kencan Dengan Tuhan - Kamis, 9 Juli 2026Bacaan: "Hidup dan mati dikuasai lidah, siapa suka menggemakannya, akan memakan buahnya." (Amsal 18:21)Renungan: Suatu hari seorang istri mengeluh karena minggu ini ia terlalu lelah. Kerjaan menumpuk, anak rewel minta ditemenin belajar. Suaminya pulang kerja terus rebahan main HP. Tanpa sadar ia kesal dan berkata kepada suaminya: "Kamu sih tahunya cuma enak-enak rebahan. Gak pernah mikirin rumah ini!" Suaminya pun diam. Malam itu suasana rumah menjadi dingin. Dua hari kemudian giliran ia yang sakit. Anak-anak yang biasanya deket dengannya menjadi takut karena melihat papa mamanya tegang. Ia pun tersadar. Satu kalimat emosinya malam itu "mematikan" suasana rumah selama dua hari. Padahal kalau ia bilang: "Pa, aku capek. Boleh tolong temenin anak belajar 30 menit?" pasti jawabannya berbeda. Amsal 18:21 ini berisi peringatan keras dari Raja Salomo tentang kuasa dari kata-kata: "Hidup dan mati dikuasai lidah". Di rumah, lidah kita bisa jadi sumber kehidupan atau sumber kematian. Dengan kata-kata kita bisa menghidupkan semangat pasangan, menguatkan anak yang gagal, memberkati keluarga. Tapi dengan kata-kata juga kita bisa melukai hati pasangan, mematikan semangat anak, dan merusak keharmonisan rumah. Rumah tangga kita adalah cermin dari apa yang sering kita ucapkan. Suka mengeluh, maka rumah penuh keluhan. Suka mengucap syukur dan menguatkan, maka rumah penuh damai. Keluarga adalah tempat pertama kita latihan memakai lidah. Tiga hal yang bisa kita latih mulai saat ini: 1. Ganti kritik dengan permintaan. Dari perkataan, "Aku sibuk, jadi lupa" menjadi "Sayang, boleh tolong ingetin aku ya" 2. Perbanyak kata penguat untuk anak. Perkataan, "Mama bangga kamu sudah berusaha", lebih menghidupkan daripada "Nilainya kok segitu-segitu aja".3. Doa berkat sebelum tidur. Ucapkan satu kalimat berkat untuk tiap anggota keluarga. Itu seperti menyiram tanaman di rumah. Ingat, anak-anak kita tidak akan ingat seberapa rapi rumah kita. Tapi mereka akan ingat: "Di rumah ini, kata-kata apa yang paling sering ia dengar." Tuhan Yesus memberkati. DOA:Tuhan Yesus, ampunilah aku kalau selama ini lidahku sering melukai orang-orang yang paling aku kasihi di rumah. Ajarilah aku menjadi pembawa damai di tengah keluargaku. Berikan hikmat supaya setiap kata yang keluar dari mulutku adalah kata yang membangun, menguatkan, dan memberkati. Amin. (Dod).

Ganti ban, dibawah tronton, Kepet main sendiri, banyak sepeda.

Sedang menjadi headline mengenai kasus korupsi pengadaan laptop chromebook oleh Nadiem Makarim (mantan Menteri Pendidikan). Beliau dituntut oleh jaksa 10 tahun penjara serta denda pengembalian kerugian negara sebesar 800M. Tuntutan tersebut sudah divonis oleh hakim, dan masyarakat banyak yang membela Nadiem karena tidak adanya bukti yang cukup kuat untuk memvonis beliau.Sudah hadir di studio saya, Bapak Mahfud MD, Mantan Menteri Koordinator Bidang Politik dan Keamanan Indonesia yang juga seorang guru besar hukum tata negara. Kita akan minta pendapat beliau mengenai kasus korupsi ini. Simak selengkapnya!

Usul Tafsir Kitab Fauzul Kabeer EP31 - Maulana Abdul Hadi Yaakob - Ganti dhomir muzakkar dgn muannats &sebaliknya &ganti lafaz mufrad dgn lawan

Gangguan kelistrikan yang terjadi di sejumlah wilayah Sumatra ini mengakibatkan UMKM maupun pengusaha ayam merasa banyak dirugikan.

Huwaduh … intinya kelajjutan ep 1 drapod ini .. dengerin dlu deh kalo ga tau

Gubernur Jawa Barat Dedi Mulyadi berencana mengganti palang pintu perlintasan kereta api manual menjadi sistem digital guna meningkatkan efektivitas dan keamanan di perlintasan sebidang. Proyek yang diprioritaskan di wilayah Bekasi ini diperkirakan rampung dalam dua minggu ke depan dengan estimasi anggaran mencapai satu miliar rupiah. Selain modernisasi teknologi pria yang akrab disapa KDM tersebut juga memerintahkan jajaran pemerintah daerah untuk memastikan petugas resmi berjaga di lokasi guna meminimalisasi praktik penjagaan oleh pihak tidak resmi sekaligus mencegah terjadinya kecelakaan lalu lintas.

Looking to step into a new career? You're not the only one, the stats suggest. No matter your age, background or whether English is your first language, a career change at some point is almost inevitable nowadays. In Australia, support is available to help you through the process. - Ingin melangkah ke karir baru? Anda bukan satu-satunya, statistik menyarankan. Tidak peduli usia Anda, latar belakang atau apakah bahasa Inggris adalah bahasa pertama Anda, perubahan karir di beberapa titik hampir tak terhindarkan saat ini. Di Australia, dukungan tersedia untuk membantu Anda melalui proses tersebut.

AMAZING GRACE PROGRAM - PS. TIMOTHY ROY, M.A., D.Min., Ph.D - GEREJA KRISTUS PENEBUS

Get updates for my new book: https://Theperfectportfoliobook.com  -----  Anu Ganti joins The Long Term Investor to break down the newest SPIVA U.S. Scorecard and what it says about the long-running active versus index debate. This conversation goes beyond the headline numbers to explore why beating the market remains so difficult, why finding the managers who can keep doing it is even harder, and what investors should understand before choosing any index-based fund. Listen now and learn: ► What the latest SPIVA U.S. Scorecard revealed about active manager underperformance ► What the Persistence Scorecard says about trying to identify winning managers ahead of time ► How index-based products are being used for both long-term investing and tactical trading ► What investors should know about index methodology before choosing a fund   Visit www.TheLongTermInvestor.com for show notes, free resources, and a place to submit questions.   Editing and post-production work for this episode was provided by The Podcast Consultant (⁠https://thepodcastconsultant.com⁠)   Disclosure: This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. The commentary in this "post" (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Plancorp LLC employees providing such comments, and should not be regarded the views of Plancorp LLC. or its respective affiliates or as a description of advisory services provided by Plancorp LLC or performance returns of any Plancorp LLC client. References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see disclosures here.

Nang lipulin ng sumpa ng isang mangkukulam ang kanyang pamilya, mapipilitan si Noli na itaya ang lahat upang ipagtanggol ang kanyang buntis na asawa mula sa malagim na pag-atake ng isang mabagsik na aswang sa kalagitnaan ng gabi.

Isang masayang pamilya ang nakatakdang mawasak nang matuklasan ni Raphael na ang napangasawa ng kanyang kuya ay isang mapanganib at mapagkunwaring mambabarang. Sa kanyang desperasyong iligtas ang kapatid mula sa patibong, siya naman ang naging puntirya ng nakakikilabot na itim na mahika na nagdulot ng matinding pasakit sa kanyang katawan. Hanggang saan ang kayang isakripisyo ni Raphael para labanan ang kasamaan, kung ang mismong kapalit nito ay ang sarili niyang buhay?

Pakar menilai langkah Amerika Serikat terhadap Iran tidak semata soal program nuklir. Ada pandangan yang menyebut tujuan lebih luas, termasuk dorongan perubahan rezim di Teheran, yang berpotensi memicu eskalasi geopolitik baru.

Powering the Future with India's Ancient WisdomProf Ganti Suryanarayana Murthy is the National Coordinator of the Indian Knowledge Systems (IKS) Division, Ministry of Education, Government of India, at AICTE, New Delhi. He also serves as Professor in the Department of Biosciences and Biomedical Engineering at IIT Indore.He was among the distinguished guest speakers at the 2nd Global Vedic Conference held at Prasanthi Nilayam in January 2026, where he offered valuable insights from the integrated perspective of Indian Knowledge Systems, contemporary science, and education.Subsequently, during his interaction at the Sri Sathya Sai Media Centre, he eloquently expounded on the relevance, revival, and renaissance of ancient India's sacred knowledge traditions, highlighting their enduring significance in the modern world.

Pemilu masih sekitar tiga tahun lagi. Namun, sejumlah partai sudah menyatakan dukungan agar Prabowo maju lagi. Meski demikian, Gibran tak diusulkan untuk mendampingi lagi. PAN malah menyodorkan Zulkifli Hasan sebagai pasangan.Benarkah koalisi partai pendukung Prabowo-Gibrantak solid lagi?

Ada sebuah surat pembaca yang mengeluhkan bahwa kejadian banjir ini selalu terulang-ulang lagi setiap tahunnya.

Awakdewe teko maneh rek!

Keputusan organisasi relawan Projo untuk melepas siluet wajah Joko Widodo dari logo resminya memunculkan spekulasi publik. Selama ini, Projo dikenal sebagai barisan pendukung setia Jokowi sejak masa kampanye Pilpres 2014. Identitas visual mereka pun erat melekat pada sosok sang presiden.Perubahan logo itu disebut sebagai bagian dari transformasi organisasi menghadapi dinamika politik terbaru di bawah kepemimpinan Presiden Prabowo Subianto. Langkah ini mengisyaratkan Projo tengah menyiapkan babak baru perjalanan politiknya—dari sekadar relawan personalitas, menuju kelompok pendukung pemerintahan yang lebih luas dan adaptif.Namun pertanyaannya: apakah ini sinyal bergesernya orientasi politik Projo? Ataukah hanya upaya memperkuat posisi dalam peta kekuasaan saat ini?Pengamat menilai, hilangnya wajah Jokowi bisa dibaca sebagai strategi menjaga jarak simbolik, sembari tetap mengklaim sebagai bagian dari perjuangan politik nasional. Dengan begitu, Projo tidak lagi terkunci pada figur tunggal, melainkan membuka ruang untuk agenda politik yang lebih luas, termasuk dukungan penuh terhadap pemerintahan Prabowo-Gibran.Meski demikian, publik tentu menunggu bagaimana arah langkah konkrit Projo setelah perubahan ini. Apakah Projo akan tetap menjadi representasi politik Jokowi di panggung nasional, atau berubah menjadi kekuatan relawan yang sepenuhnya mengikuti arus kebijakan pemerintahan baru? Waktu dan sikap politik mereka ke depan akan menjawabnya.Talk :: Advokat Senior/Relawan Merah Putih, C. Suhadi &Direktur Emrus Corner/Pakar Komunikasi Politik UPH, Dr Emrus Sihombing

Program Makan Bergizi Gratis  (MBG) awalnya sebagai solusi untuk mengatasi stunting dan memenuhi kebutuhan gizi masyarakat, namun kini menjadi ironi yang menyedihkan di berbagai wilayah Indonesia.Hal ini karena setidaknya, lebih dari 5.000 siswa di Indonesia telah menjadi korban keracunan seusai menyantap menu program MBG ini.Pemerintah pun diminta untuk segera mengevaluasi dan membenahi pelaksanaan program MBG, karna dianggap melanggar hak dasar masyarakat atas pangan yang aman dan berkualitas. Mencari solusi dari berbagai kasus keracunan MBG yang sudah diberitakan media internasional, dihentikan sementara atau ganti uang tunai?  1. Ketua PB PGRI yg jg Pengamat Pendidikan Islam UIN Jakarta, Dr Jejen Musfah MA2.Ketua Forum Orang Tua Siswa (Fortusis) - Jabar Dwi Subawanto

Reshuffle kabinet di era Prabowo Subianto tak ada bedanya dengan era presiden sebelumnya: hanya sekadar ganti pemain dan bagi-bagi jabatan. Perombakan yang grasah-grusuh ini juga tak menyentuh akar masalah. Presiden melakukan reshuffle sekadar merespons demonstrasi yang berakhir rusuh pada Agustus lalu. Tanpa pendekatan yang berpihak kepada orang banyak, seberapa pun sering gonta-ganti menteri, masalah laten gagalnya perbaikan kinerja pemerintah akan terus berulang. - - - Kunjungi⁠ s.id/bacatempo untuk mendapatkan diskon berlangganan Tempo Digital. Unduh aplikasi⁠⁠ Tempo⁠⁠ untuk membaca berbagai liputan mendalam Tempo. Powered by Firstory Hosting

Ratusan kendaraan yang terendam banjir di basement Pasar Badung, Bali, mulai dievakuasi. Mendapati hal itu, Pemprov Bali menyatakan siap ganti kerugian para pedagang.

Saat Khotbah di atas bukit, Yesus mengarahkan kembali kepada maksud & makna asli, memperbaiki penafsiran yang salah, berbicara menentang penafsiran para rabi saat itu, yang selama berabad-abad telah menyimpang dari tujuan awal hukum-hukum ini.

Saat Khotbah di atas bukit, Yesus mengarahkan kembali kepada maksud & makna asli, memperbaiki penafsiran yang salah, berbicara menentang penafsiran para rabi saat itu, yang selama berabad-abad telah menyimpang dari tujuan awal hukum-hukum ini.

Mula sa MALAGIM na ISIP ni DRAVEN BLACK!LISTEN AT YOUR OWN RISK! Hosted on Acast. See acast.com/privacy for more information.

This Episode is Sponsored by BingoPlusWant to be a millionaire? Come and try the first online Poker Casino in the Philippines using BingoPlus app. Download BingoPlus App Here GooglePlay: https://play.google.com/store/apps/details?id=com.intech.c66appApple Appstore: https://apps.apple.com/ph/app/bingoplus-bingo-tongits-slot/id1612030383Bingo sa Saya, Plus sa Panalo!Ang Kwentong Takipsilim ay dadalhin kayo sa mundo ng katatakutan at kababalaghan. True stories tagalog horror at tagalog fiction. #tagaloghorrorstoriesNais mo rin bang magpadala ng iyong karanasang nakakatakot? Email mo lang sa stories@kwentongtakipsilim.com o kaya naman ay imessage mo sa aming FBSupport KT, Check our Merch now !https://takipsilimclothing.com/Sitio Bangungot Podcasthttps://open.spotify.com/show/5PLrpsyco5qfFeJ5jygHsJ?si=28ef14f811664bcaFor Business Inquiries and story submissionstories@kwentongtakipsilim.com Hosted on Acast. See acast.com/privacy for more information.

Kemendikdasmen menyatakan bahwa adanya kebijakan tes kemampuan akademik bagi siswa di sekolah pada tahun ini yang mendapat beragam respon dari masyarakat.

In today's episode, supported by Thermo Fisher Scientific, we had the pleasure of speaking with Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP, about the FDA approval of the Oncomine DX Express Test for use as a companion diagnostic for sunvozertinib (Zegfrovy) in EGFR exon 20 insertion mutation–positive non–small cell lung cancer and for use in tumor profiling. Dr Ganti is a professor in the University of Nebraska Medical Center (UNMC) Division of Oncology & Hematology, the Dr. and Mrs. D. Leon UMNC Research Fund Chair in Internal Medicine, and the associate director for Clinical Research at the Fred & Pamela Buffett Cancer Center in Omaha. Dr Cushman is the Henry F. Krous Professor of Pathology, a professor in the UNMC Department of Pathology, Microbiology and Immunology, director of the Division of Diagnostic Molecular Pathology and Human Genetics, medical director of the Molecular Diagnostics and Personalized Medicine Laboratory at Nebraska Medicine, director of the Molecular Genetic Pathology Fellowship Program, and associate director of the UMNC MD-PhD Scholars Program.  In our exclusive interview, Drs Ganti and Cushman discussed the significance of the launch of the Oncomine DX Express Test, the benefits and limitations of rapid next-generation sequencing, and features that set Oncomine DX apart from other available tests. 

Isang nakakakilabot na kuwento ni Elias mula sa Bukidnon—isang ama, isang empleyado, at isang saksi sa kapangyarihang hindi kayang ipaliwanag ng agham at lohika. Dito mo maririnig ang misteryo sa likod ng agimat, medalyon, at mga nilalang na hindi kayang makita ng karaniwang mata, at kung paanong ang kabutihan at kasamaan ay naglalaban sa mundong nilukob ng hiwaga. Ang boss niyang si Mang Allan ang may hawak ng kapangyarihan—subalit sa huli, sino nga ba ang tunay na api, at sino ang may karapatang gumanti?

Perubahan budaya organisasi adalah transformasi mendalam pada nilai-nilai, keyakinan, norma, dan kebiasaan bersama yang membentuk cara karyawan berinteraksi dan bekerja. Ini bukan sekadar penyesuaian strategi atau struktur, melainkan pergeseran pada inti identitas perusahaan. Perubahan ini dapat bermanifestasi dalam berbagai aspek, mulai dari cara pengambilan keputusan, komunikasi internal, hingga pendekatan terhadap inovasi dan layanan pelanggan. Melakukan perubahan budaya seringkali menjadi keharusan karena berbagai alasan, seperti menghadapi disrupsi pasar, meningkatkan efisiensi, atau beradaptasi dengan teknologi baru. Tanpa perubahan budaya yang tepat, organisasi bisa tertinggal, kehilangan talenta terbaik, atau bahkan mengalami penurunan kinerja yang signifikan. Budaya yang stagnan dapat menjadi penghalang inovasi dan menghambat kemampuan perusahaan untuk merespons tantangan eksternal. Untuk melakukan perubahan budaya secara efektif, mulailah dengan visi yang jelas dan kepemimpinan yang kuat dari atas. Libatkan karyawan di semua tingkatan, komunikasikan alasan di balik perubahan secara transparan, dan berikan pelatihan serta dukungan yang diperlukan. Penting untuk merayakan setiap kemajuan kecil dan secara konsisten memperkuat perilaku yang diinginkan melalui penghargaan dan pengakuan. Ingat, perubahan budaya adalah sebuah perjalanan yang membutuhkan waktu, kesabaran, dan komitmen berkelanjutan.

Welcome to the Social-Engineer Podcast: The Doctor Is In Series – where we will discuss understandings and developments in the field of psychology.   In today's episode, Chris and Abbie are discussing the Bystander Effect. They will talk about the many different ways it presents itself as well as how to avoid it and what you can do if you find yourself victim of it. [March 3, 2025]   00:00 - Intro 00:14 - Dr. Abbie Maroño Intro 00:45 - Intro Links -          Social-Engineer.com - http://www.social-engineer.com/ -          Managed Voice Phishing - https://www.social-engineer.com/services/vishing-service/ -          Managed Email Phishing - https://www.social-engineer.com/services/se-phishing-service/ -          Adversarial Simulations - https://www.social-engineer.com/services/social-engineering-penetration-test/ -          Social-Engineer channel on SLACK - https://social-engineering-hq.slack.com/ssb -          CLUTCH - http://www.pro-rock.com/ -          innocentlivesfoundation.org - http://www.innocentlivesfoundation.org/                                 03:06 - The Topic of the Day: The Bystander Effect 03:16 - Defining the Bystander Effect 05:14 - The Smoke Filled Room 09:03 - The Advantage of CCTV 11:13 - The Ambiguity Factor 12:53 - Gender Dynamics 15:20 - Self-Construal 16:43 - Reverse the Roles 21:21 - Bystanding Online 22:59 - It's Easier to be Negative 25:34 - Fear Factor 27:53 - Assigning Responsibility 30:34 - Education is Key 31:19 - Just Ask! 32:40 - Wrap Up 32:49 - Next Month: Why Do We Cry? 33:12 - Outro     -          www.social-engineer.com -          www.innocentlivesfoundation.org   Find us online: -          Twitter: @DrAbbieofficial -          LinkedIn: linkedin.com/in/dr-abbie-maroño-phd -          Instagram: @DoctorAbbieofficial -          Twitter: @humanhacker -          LinkedIn: linkedin.com/in/christopherhadnagy     References: Bauman, S., Yoon, J., Iurino, C., & Hackett, L. (2020). Experiences of adolescent witnesses to peer victimization: The bystander effect. Journal of school psychology, 80, 1-14. Fadilah, I. N., & Ansyah, E. H. (2022). The Relationship Between The Bystander Effect and Prososial Behavior in Students Of The Faculty Of Psychology And Educational Sciences At University. Academia Open, 7, 10-21070. Ganti, N., & Baek, S. (2021). Why People Stand By: A Comprehensive Study About the Bystander Effect. Journal of Student Research, 10(1). Havlik, J. L., Vieira Sugano, Y. Y., Jacobi, M. C., Kukreja, R. R., Jacobi, J. H. C., & Mason, P. (2020). The bystander effect in rats. Science Advances, 6(28), eabb4205. Kettrey, H. H., & Marx, R. A. (2021). Effects of bystander sexual assault prevention programs on promoting intervention skills and combatting the bystander effect: A systematic review and meta-analysis. Journal of experimental criminology, 17, 343-367. Levine, M., Philpot, R., & Kovalenko, A. G. (2020). Rethinking the bystander effect in violence reduction training programs. Social Issues and Policy Review, 14(1), 273-296. Liu, D., Liu, X., & Wu, S. (2022, June). A Literature Review of Diffusion of Responsibility Phenomenon. In 2022 8th International Conference on Humanities and Social Science Research (ICHSSR 2022) (pp. 1806-1810). Atlantis Press. Machackova, H. (2020). Bystander reactions to cyberbullying and cyberaggression: individual, contextual, and social factors. Current opinion in psychology, 36, 130-134. Madden, C., & Loh, J. (2020). Workplace cyberbullying and bystander helping behaviour. The International Journal of Human Resource Management, 31(19), 2434-2458. Szekeres, H., Halperin, E., Kende, A., & Saguy, T. (2022). Aversive Bystander Effect: Egalitarian bystanders' overestimation of confronting prejudice.

Kali ini, kita kedatangan Fernando Sindu, Chef Patron dari Cork and Screw dan Barluca Jakarta! Dalam episode kali ini, Fernando berbagi cerita menarik tentang tantangan yang dihadapi restoran ketika harus mengubah konsep agar tetap relevan di pasar. Tak hanya itu, ia juga akan mengungkap perjalanan kariernya, termasuk pengalaman seru selama trip kuliner dan latar belakangnya yang menguasai masakan Spanyol sebelum sukses di Indonesia. Tonton video selengkapnya di #RayJansonRadio#480 KETIKA RESTORAN GANTI KONSEP WITH FERNANDO SINDU | RAY JANSON RADIO Enjoy the show! Instagram: Fernando Sindu: https://www.instagram.com/fernandosindu/ DON'T FORGET TO LIKE AND SUBSCRIBE ! Ray Janson Radio is available on: Spotify: https://spoti.fi/2lEDF01 Apple Podcast: https://apple.co/2nhtizq Google Podcast: https://bit.ly/2laege8i Anchor App: https://anchor.fm/ray-janson-radio TikTok: https://www.tiktok.com/@rayjansonradio Let's talk some more: https://www.instagram.com/rayjanson #RayJansonRadio #FnBPodcast #Indonesia

Airline customers could receive full refunds and other assistance over cancelled or delayed flights under Australian law. - Penumpang pesawat dapat menerima ganti rugi penuh dan bantuan apabila mengalami pembatalan ataupun keterlambatan menurut hukum Australia.

In this episode of The Climate Stack,  Mansi sits down with Vish Ganti, a visionary product leader at the nexus of clean energy, AI, and fintech. Together, they explore the transformative potential of virtual power plants (VPPs) in reducing reliance on carbon-intensive peaker plants and stabilizing the grid. Vish sheds light on how VPPs integrate distributed energy resources (DERs) and the critical need for open standards to create a frictionless ecosystem.VPPs are a prime example of how smart software optimizations can revolutionize the deployment and utilization of physical energy assets. By leveraging software to orchestrate diverse DERs, VPPs enable more efficient energy management, reducing waste and enhancing grid reliability. Discover why simplifying communication between DERs is essential for advancing sustainable energy solutions and making power management through VPP aggregators a reality.Our Guest Vish GantiVish is currently serving as Senior Director of Product Management for Virtual Power Plants (VPPs) at Qcells, Vish specializes in developing scalable energy platforms that integrate first-party hardware with industry-leading solutions from partners like Enphase, Tesla, and SolarEdge. His expertise lies in transforming distributed energy resources into bankable grid assets through advanced edge AI technologies, enabling smarter energy systems and sustainable revenue models.Previously, Vish held leadership roles at AutoGrid, where he spearheaded the development of AutoGrid Flex, a SaaS platform for VPPs and 24x7 Carbon-Free Energy solutions, and contributed to the company's acquisition by Schneider Electric. He also worked with renowned organizations such as CPower Energy, Johnson Controls, and Lawrence Berkeley National Laboratory, focusing on demand response, DER optimization, and energy system innovation.Vish holds a Master of Science in Electrical & Energy Systems from San Francisco State University and a Bachelor of Science in Electronics & Communications from Jawaharlal Nehru Technological University. A thought leader in the clean energy space, Vish has co-authored industry-recognized publications and continues to drive impactful solutions that advance the global transition to renewable energy.https://www.linkedin.com/in/vishganti/Your Hosts Mansi Shah - Joshua Marker ClimateStack

Here we go again. A tough weekend in the FPL world for Amogh, so what better time to bring on last seasons TCF Mini League winner, Friend of the Flag, and one of our most loyal listeners Abhishek Ganti on to the pod! Ganti too had a miserable FPL GW, so this was therapy. But the sorrows don't end at FPL. Man United decided to add salt to the wounds by what can only be described as 'a performance worse than Amogh's 5 a side team'. The boys discuss all that went wrong at United, all that's going right at Chelsea and if Arsenal are indeed credible title challengers to a Rodri-less Man City. Follow us on our social media! Instagram: https://www.instagram.com/cornerflagpod/ Twitter: https://www.twitter.com/cornerflagpod/ YouTube: https://www.youtube.com/@CornerFlagPod/ Subscribe to us on Spotify, Apple Podcasts or wherever you get your pods from and don't forget to give us a 5 star review! Learn more about your ad choices. Visit megaphone.fm/adchoices

Close The Door Podcast bersama Dustin & Ditha

Double pivot andalan anda ngomongin tentang para pemain yang berganti nama

Ibadah Raya Lifehouse Community bersama Ps. Wigand Sugandi Setiap Minggu, Pk. 10:00 WIB Wang Plaza, Lt. 2

Siapa rasa tangan dia lagi power main skate dari kaki, boleh follow Fibo Malaysia untuk join komuniti gempak ni! Instagram Thinker: https://www.instagram.com/thinker.studios/?hl=en Hear us on Spotify: https://open.spotify.com/show/5KXoqorpVXT9sIVq8lYMyK Hear us on Syok: https://bm.syok.my/podcast/show/14181

MLOps podcast #196 with Numbers Station's Venky Ganti SVP, Product & Engineering and Principal Engineer, Laurel Orr, LLMs in Focus: From One-Size Fits All to Verticalized Solutions. // Abstract Dive into the realm of large language models (LLMs) as we explore the merits and limitations of 'one-size fits all' LLMs, and their role in data analytics. Through customer stories, we showcase real-world applications and contrast general LLMs with verticalized, enterprise-centric models. We address the significance of ownership structures, with a focus on open-source vs proprietary impacts on transparency and trustworthiness. Delving into the NSQL foundation models, we emphasize the importance of diverse, quality training data, especially with enterprise challenges. Lastly, we speculate on the future of LLMs, highlighting hosting solutions and the evolution towards specialized challenges. // Bio Laurel Orr Laurel Orr is a Principal Engineer at Numbers Station, a startup that applies Foundation Model technology to the enterprise data stack. Her research interests include how to use FMs to solve classically hard data-wrangling tasks and how to put FM technology into deployment. Before Numbers Station, Laurel was a postdoc at Stanford advised by Chris Re as part of the Hazy Research Labs working in the intersection of AI and data management. She graduated with a PhD in database systems from the University of Washington. Venky Orr Venky brings over two decades of experience in software engineering and technical leadership to Numbers Station as SVP of Product & Engineering. Most recently, he served as General Manager leading several initiatives on query understanding and commerce in the ads product area at Google. Before that, he was CEO and co-founder of Mesh Dynamics, the API test automation company, which was acquired by Google in 2021. Prior to Mesh Dynamics, Venky was CTO and co-founder of Alation, the enterprise data catalog company, where he led technology and helped create the new data catalog product category. // MLOps Jobs board https://mlops.pallet.xyz/jobs // MLOps Swag/Merch https://mlops-community.myshopify.com/ // Related Links Website: https://www.numbersstation.ai/ ⁠ --------------- ✌️Connect With Us ✌️ ------------- Join our slack community: https://go.mlops.community/slack Follow us on Twitter: @mlopscommunity Sign up for the next meetup: https://go.mlops.community/register Catch all episodes, blogs, newsletters, and more: https://mlops.community/ Connect with Demetrios on LinkedIn: https://www.linkedin.com/in/dpbrinkm/ Connect with Laurel on LinkedIn: https://www.linkedin.com/in/laurel-orr/ Connect with Venky on LinkedIn: https://www.linkedin.com/in/venky-ganti-2679a2/ Timestamps: [00:00] Venky's and Laurel's preferred coffee [00:36] Takeaways [03:15] Please like, share, and subscribe to our MLOps channels! [04:38] Venky's background [07:47] Laurel's at background [09:38] Data wrangling [13:45] Sequel query [19:25] One size-fits-all LLMs vs Verticalized and Specific LLMs [23:42] Model Choice Trade-offs [30:18] NSQL Foundational Models [37:26] LLM Trends in 12 Months [40:09] Data recipes being democratized [45:16] Claude and 100,000 Context [48:02] Exploring Varieties of LLMs [50:02] AI Gateway [51:07] Text-to-SQL Model Evaluation [54:00] Wrap up

Hayooo hayooo masih ada yang sering kasih kode ke pasangan gak? Meski setelah pernikahan berjalan lebih dari 5 tahun, masih kasih kode? Atau baru menikah, lebih banyak kasih kode dibanding ngasih tau secara langsung? Ternyata ada beberapa alasan, orang sering ngasih kode ke pasangan, mulai dari rasa gak enak, berasumsi ke pasangan, sampai rasa takut atau dicela saat menyampaikan sesuatu. Tapi sebetulnya boleh gak sih terus-meneruks kasih kode ke pasangan? Simak obrolan lengkapnya ya, Parents! ---------------------------------------------------------------------------------------------------------------------- TIMESTAMP 00:00 Opening 02:40 Alasan kasih kode ke pasangan 04:54 Kode bisa disampaikan dengan kalimat positif 08:23 Ganti kalimat perintah ke kalimat ajakan 13:41 Pentingnya to the point 17:04 Rasa takut ditolak membuat sulit mengungkapkan sesuatu 18:06 Summary ---------------------------------------------------------------------------------------------------------------------- Follow info & keseruan lainnya dari Parentalk di sini: ✅ INSTAGRAM: https://www.instagram.com/parentalk.id ✅ TIKTOK: https://www.tiktok.com/@parentalk_id ✅ WEBSITE: https://parentalk.id Follow account speaker di sini: ✅ INSTAGRAM: https://www.instagram.com/nuchabachri/ ✅ INSTAGRAM: https://www.instagram.com/sheggario/ #parentalk #curhatbabu #parentalkcurhatbabu

JCO PO author Dr. Apar K. Ganti shares insights into his JCO PO article, “Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.” Host Dr. Rafeh Naqash and Dr. Ganti discuss clinical decision-making regarding biopsy; HER2 amplification, mutation, and targeted therapy; drug combinations; and aspects of the TAPUR and DESTINY-Lung studies. Click here to read the article!   TRANSCRIPT Dr. Abdul Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Abdul Rafeh Naqash, Social Media Editor for JCO Precision Oncology, and Assistant Professor at the University of Oklahoma Stephenson Cancer Center.  Today we are joined by Dr. Apar Kishor Ganti. Dr. Ganti is a Professor of Medicine and associate director of clinical research at the Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center. He's also a staff physician at the VA Nebraska Western Iowa Healthcare System. Dr. Ganti is the lead author of the JCO Precision Oncology article titled "Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study," which is also the TAPUR Study.  Dr. Ganti, thank you so much for joining us today. Dr. Apar Kishor Ganti: Thank you for having me. I'm happy to be here. Dr. Abdul Rafeh Naqash: For starters, Dr. Ganti, this is one of the trials from the TAPUR Basket study. So I wanted to take this opportunity since this is an ASCO initiative that has been there for a few years now. Could you tell us a little bit of background about the TAPUR initiative, what kind of trials are being run or have been run, and how it all started, basically?  Dr. Apar Kishor Ganti: The TAPUR Study or the Targeted Agent and Profiling Utilization Registry Study is a pragmatic basket trial which evaluates the anti-tumor activity of commercially available targeted agents in patients with advanced cancers and tumors that have potentially actionable genomic alterations, like mutations, amplifications, etc. And this has multiple arms in multiple malignancies, using drugs that are currently approved in different indications and not necessarily approved for the indication that's being studied. But there's preclinical data that suggests that that particular drug may potentially be active in patients whose tumors harbor those mutations. For example, this present study that we conducted utilized a combination of pertuzumab and trastuzumab, both of which are FDA-approved for the treatment of patients with HER2-positive breast cancers. And we analyzed the efficacy of the combination of these two drugs in patients with lung cancer who had either a HER2 mutation or an amplification of HER2.  Dr. Abdul Rafeh Naqash: Thank you so much for giving us that background. Going to this study specifically, which is one of the very interesting TAPUR studies, what I'm reminded of especially is NCI-MATCH, for example, which runs on a similar premise to this study, where we've seen some successes and some not as exciting combination approach successes that is what we would have wanted to see.  For lung cancer specifically, as you and I both know and perhaps many of the listeners know, there's a lot of actionable drivers that have target therapies that are approved, could you touch on some of those to give a background on where the field currently lies and what are some of the important steps with respect to obtaining next generation sequencing, perhaps in patients. So what your practice is and what you would recommend for these individuals? Dr. Apar Kishor Ganti: Certainly, non-small cell lung cancer, or non-squamous non-small cell lung cancer, to be more precise, seems to be the poster child for next-generation sequencing. And the importance of NGS testing cannot be overemphasized in these patients. For example, right now we have multiple different drivers that have drugs approved for the management of these patients. The first among them, obviously, was EGFR or epidermal growth factor receptor. And that has been followed fairly successfully by targeting ALK, ROS1, now, more recently, RET, MET, KRAS, and HER2. So if you look at lung adenocarcinomas, almost half of the patients will have a tumor with a mutation that is targetable. And so it's very important to make sure that these patients are tested for, before initiating any therapy. What makes it more important is that the standard of care for patients with non-small cell lung cancer without driver mutations is either immunotherapy or chemoimmunotherapy. And we have found that if a patient has a driver mutation, especially EGFR or ALK, even if their PD-L1 expression is extremely high, their response to checkpoint inhibitors is negligible. And so it is important to make sure that we understand what their molecular status is before starting any treatment in these patients. And I think the key point here is that every patient with advanced non-small cell lung cancer should have next generation sequencing studies done prior to initiation of treatment. Dr. Abdul Rafeh Naqash: Absolutely. And in your practice, Dr. Ganti, do you tend to do liquid biopsies concurrently when you get a new individual with a diagnosis of lung cancer, or do you do it at some other time point?  Dr. Apar Kishor Ganti: Liquid biopsies, I tend to get them, but not as frequently as some would like. I tend to believe more in tumor biopsies, and I would get liquid biopsies only in the setting where a tumor biopsy is not feasible or if I feel that the patient needs treatment more rapidly than can be expected if I got a tissue biopsy. Liquid biopsies, in my opinion, are good, but they're very dependent on the tumor fraction that is present in the sample that you send. As you very well know, not all patients who have a driver mutation necessarily shed the mutation into the blood. And therefore, even if a patient has a driver mutation in a tumor, there is a small chance that the liquid biopsy may not detect it. So I tend to be more in favor of getting tumor biopsies for next-generation sequencing. In situations where the tumor fraction is high, the concordance between tumor biopsies and liquid biopsies is fairly good. Dr. Abdul Rafeh Naqash: Thank you so much for that very important clinical decision-making thought process. At least in my practice, when tissue is often the issue, as you very well know, where you don't either have enough tumor cells or the biopsy is just enough to tell you whether it is squamous or non-squamous and not enough for any further sequencing, I try to get liquid biopsies whenever feasible and appropriate so that at least we can rule out some of the driver alterations before I put a patient on immunotherapies, due to the concern for subsequent toxicities if there are driver alterations. But I totally agree, I think tissue is definitely the standard, gold standard. And if you have overlapping mutations in tissue and liquid, then obviously it increases your confidence of treating that individual with that targeted therapy. But in general, tissue definitely, at least we should try to emphasize, and I try to do this often when I get a call from a community oncologist. I'm pretty sure you do the same where we ask for multigene broad gene testing NGS, so that especially when you have HER2 mutations, for example, you won't necessarily capture those as you show on your study here.   Now, going to your study, Dr. Ganti, could you tell us a little bit more about HER2 mutations and amplifications? And there's different levels of evidence where amplification may not lead to expression or expression may not lead to amplification. And then there is a separate category of HER2 mutations. And a lot of what we know for HER2 is from breast cancer. And recently, in the last two to three years now, is for lung cancer also. Could you tell us about how the field is shaping from a HER2 mutational landscape, an amplification landscape, in the lung cancer field?  Dr. Apar Kishor Ganti: As you rightly said, most of our knowledge from HER2 is from the breast cancer world. And frankly, I think we've been spoiled by the data on breast cancer. So, unlike in breast cancer, lung cancer seems to have a much lower frequency of HER2 alterations. And while in breast cancer, HER2 amplification seems to be important and predictive for response to HER2-targeted agents, in lung cancer, we see a combination of mutations and amplifications. So, in a large TCGA study, mutations in HER2 seem to occur in about 2% of all lung cancers. And amplification seems to be occurring in approximately a similar proportion of different patients. So, they seem to be mutually exclusive as best as we can tell.  And, unlike in breast cancer, where HER2 amplification seems to be directly associated with protein over-expression and response to tumor, the data in lung are much less robust. And so, it is not necessarily that an amplification will translate into a prediction of response to a HER2-targeted agent. And we and certain other studies have shown that patients who have HER2 amplification may not respond as well to HER2-targeted therapy as opposed to, for example, patients with HER2 mutations. So, that seems to be the discrepancy in HER2 amplification and HER2 mutations when you look at lung cancer versus breast cancer. And that's another reason why we are doing the TAPUR study at the various arms because what works in one specific cancer with the same mutation or same abnormality may not necessarily work in other cancers. Dr. Abdul Rafeh Naqash: Absolutely. Thank you for indulging into that side of things. Now, going back to your trial, could you tell us a little bit of background on the eligibility criteria, how you chose some of the different mutations? What were the levels of evidence for some of those mutations from a pathogenicity standpoint, and then what were your endpoints, since this is a clinical trial with a Simon two-stage design?  Dr. Apar Kishor Ganti: Patients who were eligible for the trial included all patients with advanced lung cancer who did not have another FDA-approved treatment or were not candidates for another treatment. They all should have been 18 years or older at the time of diagnosis and have lung cancer with either ERBB2 amplification or we looked at 13 specific mutations, insertions, or deletions, and, if the patient had any of those abnormalities identified by any clear approved next-generation sequencing testing platform, then they would be eligible for the study. We chose these because of how frequently these specific mutations occurred in lung cancer and other cancers. And so, these 13 abnormalities were chosen from the host of HER2 mutations that you can see. Patients should not have received a previous HER2 inhibitor, obviously, and their LV ejection fraction should be normal because of the known risk of decreasing cardiac function with HER2-targeted therapy. They were treated with pertuzumab every three weeks and then combined with trastuzumab. Trastuzumab was given at a loading dose, initially of 8 milligrams per kilogram, and in subsequent cycles, we used 6 milligrams per kilogram. The dose of pertuzumab was a flat dose of 840 milligrams for the first dose and 420 milligrams for subsequent doses.  We continued the treatment till progression or excessive toxicity or patient withdrawal of consent. The endpoints were disease control, which we defined as objective response or stable disease for at least 16 weeks duration. Other endpoints were progression-free survival, overall survival, duration of response, and, of course, safety. We used a Simon two-stage design, as you said. The null hypothesis was that the disease control rate would be 15%, alternative hypothesis was 35%, the power was 85%, alpha was at 10%. So, if in the first stage, less than two out of ten patients had disease control, then the cohort would be closed for futility. If two patients or more had disease control of the first 10, then we expanded to an additional 18 patients for a total study size of 28. So, as far as safety analysis, any patient who received even a single dose of treatment was included in that safety analysis.  Dr. Abdul Rafeh Naqash: Thank you so much for giving us those details about the cohort. Going to the mutation or the amplifications, I'm looking at the cohort, so it seems like more or less, to some extent, there was an equal distribution of the mutations. 50% of individuals had mutations and then around 45%, 43% had amplifications. Did that play into your expectation of how the cohort did in terms of responses or the primary endpoints that you had set? Did you see differences based on those findings of mutations versus amplifications.  Dr. Apar Kishor Ganti: Yes, we did. The disease control rate was 37%, with an overall response rate of 11%. And when you looked at patients who had a partial response, which is three patients, all of them had ERBB2 mutation. And of the patients who had stable disease, only two patients out of seven had an amplification. Five patients had the mutation. So, again, this was similar to what we had expected, that based on previous studies, patients with mutation tend to respond better than patients with alterations. Dr. Abdul Rafeh Naqash: Definitely. And going to one of the striking figures that you have in this manuscript, of course, you have the waterfall plot, and then you have the swimmer's plot and the spider plot. I'm very intrigued personally by the spider plot, which is the Figure 3 in your paper, especially with this individual that had this long, durable partial response. I believe this was the same individual with the mutation. I believe it was this 776 insertion. Was there anything, any other aspect that could have contributed to this response, or does this mutation, does it have any strong preclinical data of why the activity offer to direct therapy might be more pronounced in this mutation that you came across?  Dr. Apar Kishor Ganti: Not to my knowledge. I don't think we found anything specific or different about this particular patient compared to the others. So, as far as the mutation itself is concerned, it's a fairly common mutation, the G776 insertion. It is one of the most common mutations seen in lung cancer, and studies have shown that patients with the mutation tend to respond. But why this patient responded so long, it's difficult to say. I wish we were able to find out, but unfortunately, we were not able to. Dr. Abdul Rafeh Naqash: Sure. Another question that I wanted to ask you since this falls into the precision medicine basket study questions. Does TAPUR have a different endpoint for different sub-studies? Because I vaguely remember coming across another paper where I believe a 16-week disease control was also the endpoint. So, is that something universal in TAPUR, or is it specific for specific tumor types and different combination approaches? Dr. Apar Kishor Ganti: I believe that this is a more generalized feature of the TAPUR study, the stable disease for 16 weeks as a marker of response. Of course, different arms have additional endpoints, but I think this is one of the more common ones. Dr. Abdul Rafeh Naqash: Now, there has been some work, as you very well pointed out in your paper as well, from others related to HER2 mutations, especially the DESTINY-Lung study. Could you tell us a little bit about that for listeners who may not be well aware of the DESTINY study with trastuzumab deruxtecan targeting the HER2 mutations? Dr. Apar Kishor Ganti: So, DESTINY-Lung01 was a study of patients with ERBB2 mutated lung cancer. That study just looked at mutation-positive patients as opposed to what we did, looking at both mutation and amplification. And that study showed an overall response rate of 55%, which was much higher and led to the approval of fam- trastuzumab-deruxtecan in this group of patients. And so, one of the differences between our study and trastuzumab deruxtecan DESTINY-Lung01 study, is that our study included patients with both mutations and amplification and our study did not include any cytotoxic drug. And I believe that was one of the big differences, which may make the results of our study intriguing and potentially useful to patients who may not be able to tolerate a cytotoxic agent. Because, as you know, fam-trastuzumab-deruxtecan has the cytotoxic binder. It's an ADC and has been known to have some toxicities. And the thing about lung cancer is that these patients are relatively frail and may not be able to tolerate it. And so, that's one of the major differences, a portion at least for this combination, even though the response rates are much smaller than what we see with fam-trastuzumab-deruxtecan. Dr. Abdul Rafeh Naqash: And from your practice, have you started using this combination from your study as a potential approach for individuals who may not be candidates for trastuzumab deruxtecan in your clinic? Dr. Apar Kishor Ganti: I have not as yet because I have not come across a patient who would be eligible for this combination. In my practice, as we have TAPUR open, we have the tucatinib-trastuzumab arm that opened after this arm closed. So my priority is to try and enroll patients onto that cohort. And so I currently have one patient on that. And as you know, this is not a very common alteration, so we don't have as many patients with this. But definitely, this would be a combination that I would put patients on if I felt that they were not a candidate for fam-trastuzumab-deruxtecan.  Dr. Abdul Rafeh Naqash: So, Dr. Ganti, what's the next step after this since your study didn't meet some of its endpoints? What are you planning, or is there a plan to expand on this through the TAPUR mechanism?   Dr. Apar Kishor Ganti: Right now, I don't think that there's a mechanism through TAPUR to expand this particular cohort because there is also another cohort that opened subsequently with tucatinib and trastuzumab. But I think it would not be unreasonable to study this combination in patients who are not candidates for fam-trastuzumab because of the differences in toxicity. So that would be where I would potentially see a role for this particular combination, and I think it should be studied in that setting. Dr. Abdul Rafeh Naqash: Excellent. Now, I try to dedicate a section of this conversation for provocative discussions that may not be addressed in your paper, but I still like to get insights from experts in the field such as yourself. So comparing it to the NCI-MATCH or some other precision medicine-based initiatives, we do often see that mutations that we think might be driving the process don't necessarily lead to really high or really promising responses to targeted therapies. So in this case, do you think, from a futuristic standpoint, a proteomic-based assay, since I think you work in the proteomic space as well, that would be an interesting way to look at whether signaling actually is altered from a mutation or an amplification, suggesting that that is driving the process, so would be a more attractive target than just looking at a mutational signature?  Dr. Apar Kishor Ganti: I think definitely that should be the way we should be looking at these kinds of studies, because even in this study, even if you look at fam-trastuzumab-deruxtecan and the DESTINY-Lung01 study, we have patients who have definite, identified drivers, and even there, only about half of the patients responded. It was much smaller in our study. But basically what I'm getting at is with the best of the drugs that we have today, only half of our patients respond with HER-2 mutations, for example. So I would definitely favor a more integrated approach to identifying those patients who would be candidates for these targeted agents and not just simply relying on a specific mutation.  Since we are being provocative, I would go one step further and say, “Hey, we have AI. And there are currently AI-based technologies which look at the entire next-generation sequencing profile and try to identify which drugs could potentially be effective in those patients based on a complete understanding of their entire tumor genetic profile, rather than just looking at one or two, or three mutations.” So that, I think, would be a much more robust approach through precision medicine. So, like you just said, that patient that we had who had a prolonged response, we don't know why he or she had a prolonged response. And maybe if we identified a pathway or pathways which were overexpressed or more active in that particular tumor setting, we would be able to identify better targets and better approaches for those patients. So I think that is the way to go in the future. Dr. Abdul Rafeh Naqash: Excellent. Thanks for indulging into that provocative discussion and hopefully maybe five years down the line when we meet again or run across each other at ASCO, we will say, “Oh, it did actually happen, that multiomics is being used in a way that is suited for the need of the patient.” So matching the right patient to the right therapy at the right time.  So, Dr. Ganti, the last section is going to be dedicated to you as an individual. So you've had a very successful, brilliant career as a clinical trialist and as a lung cancer expert. Tell us, for the sake of our listeners and perhaps some of the early career junior investigators, what your career trajectory has been briefly, and what are some of the things that you felt were successful that could provide advice and insights to people who are earlier in their careers and trying to emulate what perhaps you have done or you are doing?  Dr. Apar Kishor Ganti: Well, that is a big one. I never thought of myself as being a role model for anyone, far less someone who's at the beginning of their career. But what I have always mentioned to students and residents and fellows is basically there is no substitute for hard work. Luck plays some role in this because you need to be at the right place at the right time for some of it, but hard work definitely will pay off. And the other thing that is important is not to get disheartened if your first clinical trial gets rejected or concept gets rejected, or if your first grant gets unscored. That is part of life, and persisting is probably the best way to continue.   Also, continuing to believe in yourself. I've seen a lot of folks, especially once they get into their second or third year after fellowship when things are not going the way they want to, they start to wonder, “Am I suited for this job? Am I the right person? Am I doing this correctly? Should I be doing something else?” And I think it's just a matter of time before they will find success. And also, the other thing is, if one particular approach does not work, there are always other ways that you can look at. So, for example, if you extend a bunch of clinical trial concepts that do not work out, you could potentially look at other ways of answering questions. For example, you could do retrospective analyses, come up with provocative, hypothetical generating questions that could be answered in the future in a prospective study. So there are lots of avenues to do that. And I think I was benefited by my mentors who helped me see this relatively early in my career. Dr. Abdul Rafeh Naqash: Thank you so much, Dr. Ganti, for all those valuable insights that you've learned over your career and hopefully will help some of the listeners. Before we finish, I'm going to ask you three rapid-fire questions that hopefully will let our listeners--give them a little bit of a sneak peek into you as a person. And you get like five seconds for each question. And they're not complicated questions. My first question to you is what is your favorite food? Dr. Apar Kishor Ganti: Thai food. Dr. Abdul Rafeh Naqash: What is your favorite place to go for vacation?  Dr. Apar Kishor Ganti: South Africa.  Dr. Abdul Rafeh Naqash: And what is your favorite hobby?  Dr. Apar Kishor Ganti: Reading.  Dr. Abdul Rafeh Naqash: Well, thank you so much again, Dr. Ganti. This was a very interesting conversation and hopefully, when you or others have other TAPUR-related trial results, perhaps they will again choose JCO PO as a destination for that work.  Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Guest Bio: Dr. Apar Kishor Ganti, MD, MS, is professor of medicine and Associate Director of Clinical Research, Fred & Pamela Buffett Cancer Center at the University of Nebraska Medical Center and Staff Physician at VA Nebraska Western Iowa Health Care System.   Guest COIs: Apar Kishor Ganti, MD, MS Consulting or Advisory Role: AstraZeneca, Jazz Pharmaceuticals, Flagship Biosciences, Cardinal Health, Sanofi Genzyme, Regeneron, Eisai Research Funding: Apexigen (Inst), NEKTAR Pharmaceuticals (Inst), TopAlliance BioSciences Inc (Inst), Novartis (Inst), Iovance (Inst), Mirati Therapeutics (Inst), Chimeric Therapeutics (Inst)  

As we know, I'm a huge advocate for index investing and today on the More Money Podcast I have two guests who are sharing their expertise on the subject including some of the pitfalls of investing in actively managed funds. Anu Ganti and Joseph Nelesen, both Senior Directors of Index Investment Strategy at S&P Dow Jones Indices, are joining me today and I'm telling you, this episode is chock-full of valuable investing info! Anu is a CFA charterholder and holds her MBA in finance and economics from Columbia Business School, as well as her bachelor's degree in finance and marketing from NYU's Stern School of Business. She is often sharing her expertise with both print and broadcast media outlets and helps lead the index investment strategy team in providing research and commentary on the entire S&P DJI product set, including U.S. and global equities, thematics, commodities, fixed income, and sustainability indices. Prior to joining the team, Anu worked in the asset management space, completing a post-MBA rotational program at Russell Investments within their fixed-income research and trading divisions and also worked as a portfolio manager focusing on emerging market equities at Parametric Portfolio Associates (a subsidiary of Eaton Vance). Joseph holds a Ph.D. from Northwestern University, an MBA from the Kenan Flagler Business School at University of North Carolina, and a Bachelor of Arts with honors from the University of California at San Diego. He also helps lead the index investment strategy team, but prior to working at S&P DJI he headed iShares Institutional Factors Strategy at Blackrock and held roles in exchange-traded product research and development. Joseph also previously worked in mergers and acquisitions and corporate investment banking with Citigroup and Bear, Stearns & Co. In this episode, Joseph and Anu challenge the myth that indexing only yields average investment returns and share how SPIVA measures actively managed funds against their index benchmarks worldwide using the data and insights they've gained over the past 20 years. This episode is full of some great information and will definitely be perfect for anyone wanting to understand why index investing is a tried and true long-term investment strategy. For full episode show notes visit: https://jessicamoorhouse.com/370

In this Spotlight episode, Arianne Alcorta with @etfguide chats with Anu Ganti, Senior Director on the Index Investment Strategy Team at S&P Dow Jones Indices. Ganti breaks down the latest performance trends contained within the SPIVA scorecard, a semi-annual report on the performance trends of actively managed funds against their relevant benchmark. The SPIVA scorecard is celebrating its 20-year history and it's the go-to tool for measuring active funds vs. their corresponding benchmarks in global markets across different asset classes and investment strategiesTo learn more about the SPIVA scorecard visithttps://www.spglobal.com/spiva 

WOW!  We were SO lucky to have Dr. Ganti back to chat with us about the immune system, and various spooky viruses!   She is a wealth of bubbly knowledge and we LITERALLY could listen to her talk for hours.We hope you enjoy the live recording of our chat on Social Audio with her.Dr. Ketaki Ganti's Links:https://twitter.com/ketakiganti http://www.lowenlab.com/Bunsen and Beaker Links:The Bunsen and Beaker Website has adorable merch with hundreds of different combinations of designs and apparel- all with Printful- one of the highest quality companies we could find!www.bunsenbernerbmd.comOur Spaces Sponsor: Bark and Beyond Supplyhttps://barkandbeyondsupply.com/Bunsen and Beaker on Twitter:https://twitter.com/bunsenbernerbmdBunsen and Beaker on Facebookhttps://www.facebook.com/bunsenberner.bmd/InstaBunsandBeakshttps://www.instagram.com/bunsenberner.bmd/?hl=enSupport the showFor Science, Empathy, and Cuteness!Being Kind is a Superpower.https://twitter.com/bunsenbernerbmd

Lho baru 45 hari udah ganti aja nih Perdana Menteri Inggris. Sebenarnya apa yang terjadi? Bersama CEO Asumsi, Pangeran Siahaan kita akan membahasnya!

Brief resolved unexplained what?? MCHD paramedic, Cpt. Clayton Smith, joins Dr. Dickson to discuss an EMS approach to BRUE's. These can often be falsely reassuring to prehospital providers because the event, by definition, has resolved prior to EMS arrival. But don't get too comfortable because up to 4-5% of BRUE's can have severe underlying diagnoses as the cause. We can never talk too much "sick peds" material on the podcast. This episode will make the approach to your next BRUE a breeze. REFERENCES 1. Tieder JS, Sullivan E, et al; Brief Resolved Unexplained Event Research and Quality Improvement Network. Risk Factors and Outcomes After a Brief Resolved Unexplained Event: A Multicenter Study. Pediatrics. 2021 Jul;148(1) 2. Banerjee, P. R., Ganti, L., et al. (2019). Early On-Scene Management of Pediatric Out-of-Hospital Cardiac Arrest Can Result in Improved Likelihood for Neurologically-Intact Survival. Resuscitation, 135, 162-167.

Wow!  While this episode is a big bigger than our average show, it's packed with great stuff.  In Science News we break down an exciting and unusual finding about WHAT is pollinating stuff at night!  In Pet Science we chat about some amazing findings about dogs in environments with a language they are unfamiliar with!  Our Expert Guest this week is Dr. Ketaki Ganti who just blew us all away with her knowledge, humour, and passion for science and critical thinking.  You won't be able to get enough of her!We also have a surprise guest on Adam's section, so that's a fun thing to look forward to!For Science, Empathy, and Cuteness!Dr. Ganti's links:Twitter Link: https://twitter.com/ketakigantiLownLab:  http://www.lowenlab.com/Bunsen and Beaker Links:Never miss a thing when you sign up for our weekly newsletter!  It has all the valuable audio news, our favourite tweets of the week and a miniblog about the family!https://www.getrevue.co/profile/bunsenbernerbmd?via=twitter-profileThe Bunsen and Beaker Website has adorable merch with hundreds of different combinations of designs and apparel- all with Printful- one of the highest quality companies we could find!www.bunsenbernerbmd.comOur Spaces Sponsor: Bark and Beyond Supplyhttps://barkandbeyondsupply.com/Bunsen and Beaker on Twitter:https://twitter.com/bunsenbernerbmdBunsen and Beaker on Facebookhttps://www.facebook.com/bunsenberner.bmd/InstaBunsandBeakshttps://www.instagram.com/bunsenberner.bmd/?hl=enDiscovery MattersA collection of stories and insights on matters of discovery that advance life...Listen on: Apple Podcasts Spotify Food 4 ThoughtThis is a podcast about everything, each week we will discuss different topics over a...Listen on: Apple Podcasts Spotify We All Have SomethingA podcast about finding balance so you can live the life you want, on purpose with purposeListen on: Apple Podcasts SpotifySupport the show

June 10, 2022 The Morning Rush Hosted by: Chico, Hazel, & Markki